Towards photon radiotherapy treatment planning with high Z nanoparticle radiosensitisation agents: the Relative Biological Effective Dose (RBED) framework

Bibliographic Details
Title: Towards photon radiotherapy treatment planning with high Z nanoparticle radiosensitisation agents: the Relative Biological Effective Dose (RBED) framework
Authors: Jeremy M. C. Brown, Gerard G. Hanna, Nathanael Lampe, Balder Villagomez-Bernabe, James R. Nicol, Jonathan A. Coulter, Fred J. Currell
Source: Cancer Nanotechnology, Vol 9, Iss 1, Pp 1-13 (2018)
Publisher Information: BMC, 2018.
Publication Year: 2018
Collection: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Subject Terms: Radiotherapy, Nanoparticles, Treatment planning, Radiosensitisers, Biological effect modelling, Theranostic nanoparticles, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
More Details: Abstract A novel treatment planning framework, the Relative Biological Effective Dose (RBED), for high Z nanoparticle (NP)-enhanced photon radiotherapy is developed and tested in silico for the medical exemplar of neoadjuvant (preoperative) breast cancer MV photon radiotherapy. Two different treatment scenarios, conventional and high Z NP enhanced, were explored with a custom Geant4 application that was developed to emulate the administration of a single 2 Gy fraction as part of a 50 Gy radiotherapy treatment plan. It was illustrated that there was less than a 1% difference in the dose deposition throughout the standard and high Z NP-doped adult female phantom. Application of the RBED framework found that the extent of possible biological response with high Z NP doping was great than expected via the dose deposition alone. It is anticipated that this framework will assist the scientific community in future high Z NP-enhanced in-silico, pre-clinical and clinical trials.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1868-6958
1868-6966
Relation: http://link.springer.com/article/10.1186/s12645-018-0043-7; https://doaj.org/toc/1868-6958; https://doaj.org/toc/1868-6966
DOI: 10.1186/s12645-018-0043-7
Access URL: https://doaj.org/article/dc8bcf0877f34e35a7fc746e9975d94b
Accession Number: edsdoj.8bcf0877f34e35a7fc746e9975d94b
Database: Directory of Open Access Journals
More Details
ISSN:18686958
18686966
DOI:10.1186/s12645-018-0043-7
Published in:Cancer Nanotechnology
Language:English